Innovations in Pharmacotherapy – Focus on Factor XI Inhibitors

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Equity/Stock(s)/Options - Elixir Medical, Stel, ControlRad (spouse)
• AMA - JAMA Cardiology (Associate Editor), ACC (BOT Member, SC Member CTR Program) - AMA - JAMA Cardiology (Associate Editor), ACC (BOT Member, SC Member CTR Program)
• Consultant Fee/Honoraria/Speaker's Bureau - Elixir Medical, IQVIA, Medtronic, Medscape/WebMD Global, NovoNordisk
• No Fees - SCAI (Women in Innovations Committee Member), Faculty Cardiovascular Research Foundation (CRF), Women as One (Founding Director)
• Grant Support/Research Contract - Abbott, Alleviant Medical, Beth Israel Deaconess Medical Center, Concept Medical, Cordis, Elixir Medical, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, Mediasphere Medical, Medtronic, Novartis, Protembis GmbH, RM Global Bioaccess